David Sinclair Longevity: How His Protocol Compares to Similar Public Figures

Who Is David Sinclair and What Does His Longevity Protocol Include?

David Sinclair is a professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research. His 2019 book Lifespan popularized the "Information Theory of Aging," which frames cellular aging as a loss of epigenetic information rather than simple DNA damage. He is one of the most cited researchers in the field of sirtuins, a family of NAD+-dependent deacylases linked to stress response and longevity pathways.

What Sinclair Reports Taking

In multiple podcast appearances, including episodes on the Huberman Lab and his own Lifespan podcast, Sinclair has disclosed his personal supplement and drug stack. As of his most recent public disclosures through 2024, he reports taking:

• NMN (nicotinamide mononucleotide): approximately 1 gram per day, taken in the morning
• Resveratrol: approximately 1 gram per day, taken with yogurt or another fat source to improve absorption
• Metformin: 1 gram per day, taken at night (skipped on days of intense exercise)
• Quercetin and fisetin: periodic high-dose cycles, described as potential senolytics
• Spermidine: daily supplementation
• Vitamin D3 (4,000 to 5,000 IU) combined with vitamin K2
• Low-dose aspirin: 83 mg daily

Sinclair consistently frames these as personal choices based on his reading of preclinical and early human data, not as formal medical recommendations.

The Science He Cites

Sinclair's protocol draws heavily on NAD+ biology. NAD+ levels fall with age in multiple human tissues, and preclinical data suggest raising NAD+ through precursors like NMN may activate SIRT1 and other sirtuins. A 2023 randomized controlled trial published in Nature Aging (N=66) found that 12 weeks of NMN supplementation (250 mg/day) improved muscle insulin sensitivity in postmenopausal women with prediabetes [1]. That is a meaningful but narrow finding. Sinclair's own laboratory has published extensively on sirtuin activation and NAD+ in model organisms, including a 2013 Cell paper showing that raising NAD+ in aged mice improved mitochondrial function within one week [2].

Metformin's longevity signal comes largely from observational data. A 2014 study in Aging Cell (N=78,241 matched pairs) found that diabetic patients on metformin lived longer than matched non-diabetic controls not taking the drug [3]. The TAME (Targeting Aging with Metformin) trial, funded by the American Federation for Aging Research and currently enrolling approximately 3,000 participants at 14 U.S. Sites, is the first prospective RCT designed to test whether metformin delays aging-related outcomes. Results are not yet available.

Peter Attia: Clinical Rigor Over Supplement Stacking

Peter Attia is a physician and author of Outlive (2023). His training is in surgical oncology and his longevity practice emphasizes what he calls "Medicine 3.0," a framework built around early detection, personalized biomarker tracking, and exercise as the single most evidence-backed longevity intervention.

Where Attia Agrees with Sinclair

Both figures prioritize sleep quality as a foundational variable. Both track continuous glucose monitoring data. Both have discussed the potential of rapamycin, an mTOR inhibitor. Attia has reported taking low-dose rapamycin (approximately 6 mg once weekly) off-label, a regimen supported in part by a 2009 Nature paper showing that rapamycin extended median lifespan in genetically heterogeneous mice by 9 to 14% even when started late in life [4].

Where Attia Diverges Sharply

Attia is publicly skeptical of both metformin and NMN for longevity in healthy, non-diabetic individuals. His concern about metformin centers on a signal from the MILES trial (N=53), which found that 6 weeks of metformin at 1,700 mg/day blunted the mitochondrial and strength adaptations to resistance exercise compared to placebo [5]. For NMN, Attia argues the human RCT data are too short-duration and too narrowly scoped to justify routine use. He does not publicly disclose a supplement stack of the same breadth as Sinclair's.

Attia's protocol concentrates on Zone 2 aerobic training (150+ minutes per week), VO2 max development, resistance training for muscle mass and strength, and early cancer screening. He calls exercise "the most potent longevity drug we have" and cites data showing that the top quintile of cardiorespiratory fitness carries a roughly 5-fold lower all-cause mortality risk compared to the bottom quintile, based on a retrospective analysis of 122,007 patients published in JAMA Network Open [6].

Bryan Johnson: The Blueprint Protocol and Quantified Self-Experimentation

Bryan Johnson, the entrepreneur behind Braintree, funds what he calls "Project Blueprint," a self-experimentation program spending approximately $2 million per year on longevity interventions. His team of 30+ physicians monitors hundreds of biomarkers monthly.

Overlap with Sinclair

Johnson takes NMN and NR (nicotinamide riboside) as NAD+ precursors, overlapping directly with Sinclair's NMN use. Both follow plant-forward, calorie-conscious diets. Johnson's protocol also includes spermidine and several compounds Sinclair mentions, including rapamycin and metformin.

Key Differences

Johnson's approach is more aggressive in its pharmaceutical component and more rigorous in its measurement cadence. He has reported taking over 100 pills per day at various points. His team publishes periodic open-access reports on his biological age measurements using epigenetic clocks, DEXA scans, and organ-specific aging algorithms. In 2023, his team published data showing his measured pace of aging (via the DunedinPACE epigenetic clock) at 0.76, meaning his epigenome appeared to be aging at 76% of the expected rate for his chronological age. The paper has not yet been peer-reviewed in a top-tier journal, and Sinclair has noted publicly that methodological choices in epigenetic clock selection can significantly shift results.

Sinclair's protocol is self-directed and disclosed informally through media. Johnson's is supervised by a clinical team with systematic measurement. That is a meaningful structural difference when evaluating what either protocol can actually tell us.

Andrew Huberman: Behavioral Protocols First, Supplements Second

Andrew Huberman is a Stanford neuroscientist and host of the Huberman Lab podcast. His public longevity approach foregrounds behavioral interventions: morning sunlight exposure, cold exposure, specific sleep protocols, and deliberate heat stress through sauna use.

Where He and Sinclair Overlap

Huberman has discussed NMN and NR positively and has disclosed taking NMN at various points. Both figures discuss resveratrol, though Huberman is more equivocal about its benefits than Sinclair. Both strongly advocate for time-restricted eating and discuss its interaction with NAD+ and mTOR pathways.

Huberman's Sauna Data

Huberman frequently cites a 2018 prospective cohort study from Finland (N=2,315, median follow-up 15 years) showing that sauna use 4 to 7 times per week was associated with a 40% reduction in all-cause mortality compared to once-weekly use [7]. Sinclair acknowledges hormetic stressors like heat and cold but does not feature them as prominently in his disclosed stack.

Huberman's supplement disclosure includes alpha-GPC, tongkat ali, ashwagandha, and compounds targeting testosterone optimization. Sinclair's stack does not include these, reflecting different primary targets: Huberman emphasizes neuroendocrine performance, while Sinclair focuses on aging biology.

Rhonda Patrick: Micronutrient Optimization and Heat Stress

Rhonda Patrick holds a Ph.D. In biomedical science and is known for her work on micronutrient insufficiencies and their role in accelerated aging. Her protocol overlaps with Sinclair's in vitamin D3/K2 use, but she places considerably more emphasis on omega-3 fatty acids (specifically EPA and DHA), magnesium, and sulforaphane from broccoli sprouts.

Patrick cites a 2022 RCT (N=13,085) published in the New England Journal of Medicine showing that omega-3 supplementation (1 g/day EPA+DHA) reduced the risk of major cardiovascular events by 7% in the VITAL trial extension, though the primary VITAL trial found no significant benefit in the general population [8]. Her approach to longevity is more micronutrient-focused than either Sinclair's or Attia's.

Sinclair rarely emphasizes omega-3s or sulforaphane in his public disclosures, which reflects his primary scientific frame: epigenetic and sirtuin biology rather than micronutrient sufficiency.

Head-to-Head Comparison: Key Protocol Elements

The table below synthesizes publicly disclosed protocol elements across the five figures. All disclosures are from public sources (podcasts, books, published reports). "Inferred" indicates the compound is consistent with their stated philosophy but not explicitly confirmed in recent public statements.

| Compound / Intervention | Sinclair | Attia | Johnson | Huberman | Patrick | |---|---|---|---|---|---| | NMN or NR | NMN, ~1 g/day | Not reported | NMN + NR | NMN (disclosed) | NR (disclosed) | | Metformin | 1 g/day | Discontinued (exercise concern) | Yes | Not reported | Not reported | | Rapamycin | Not prominently disclosed | ~6 mg/week | Yes | Not reported | Not reported | | Resveratrol | ~1 g/day | Skeptical, not taking | Inferred | Equivocal | Not prominently | | Vitamin D3 | 4,000 to 5,000 IU | Yes | Yes | Yes | Yes (higher dose) | | Exercise emphasis | Moderate disclosure | Very high (Zone 2, VO2 max) | Structured program | High (resistance + cardio) | High | | Diet pattern | Plant-forward, intermittent fasting | Low-carb, time-restricted | Vegan "Blueprint" diet | Time-restricted | Whole food, anti-inflammatory | | Epigenetic clock tracking | Yes (research context) | Yes (clinically) | Yes (monthly) | Occasional | Occasional | | Sauna / heat | Mentioned | Yes | Yes | Strongly emphasized | Strongly emphasized |

The Evidence Gap: What the Clinical Trials Actually Show

The honest picture is that no intervention has yet demonstrated lifespan extension in a well-powered human RCT. The table above reflects protocols built on a combination of strong mechanistic rationale, animal data, observational human studies, and short-duration human trials.

NMN and NAD+ Precursors

The most rigorous human NMN RCT to date is a 2023 trial published in Nature Aging (N=66, 12 weeks, 250 mg/day), which showed improved insulin sensitivity in postmenopausal prediabetic women but no statistically significant effect on body composition or other primary aging biomarkers [1]. A separate 2022 RCT (N=108, 10 weeks) by Igarashi et al. Found that 250 mg/day NMN increased blood NAD+ metabolite levels and modestly improved walking speed in older adults [9]. Neither trial addresses lifespan.

Metformin and TAME

The TAME trial is expected to report primary endpoints no earlier than 2027. Until then, metformin's use in non-diabetic individuals for longevity remains entirely off-label and based on observational signals. The FDA has not approved metformin for any indication other than type 2 diabetes management.

Resveratrol

High-dose resveratrol in humans has produced disappointing results relative to the excitement generated by preclinical studies. A 2012 Cochrane-style systematic review and a 2014 JAMA Internal Medicine study (N=783, Chianti cohort) found no significant association between urinary resveratrol metabolites (a proxy for dietary intake) and inflammatory markers, cardiovascular disease, cancer incidence, or mortality [10]. Sinclair continues to take resveratrol based on its role as a proposed SIRT1 activator, though the direct-activation mechanism has been contested in the literature.

What Distinguishes Sinclair's Approach From His Peers

Sinclair occupies a specific niche: he is simultaneously a bench scientist whose laboratory publishes primary research on aging mechanisms and a public intellectual who discloses his own protocol. This dual role creates both authority and potential bias. He has financial ties to supplement companies (he co-founded Metro International Biotech, which manufactures NMN), a fact he has disclosed publicly and one that clinicians and readers should factor into their assessment of his recommendations.

Attia separates his clinical practice from personal financial interests in supplements more clearly than Sinclair does. Johnson's protocol is the most operationally rigorous but the least generalizable, given its cost and the absence of peer-reviewed outcome data. Huberman and Patrick occupy a middle ground: credentialed communicators whose protocols are largely accessible and behaviorally grounded.

None of these figures represents a peer-reviewed, consensus-backed longevity protocol. The Endocrine Society and the American College of Physicians have not issued guidelines endorsing NMN, resveratrol, or metformin for longevity in healthy adults. The American Diabetes Association's 2024 Standards of Care confirm metformin's indication is limited to glycemic management in type 2 diabetes [11].

Clinical Takeaway for Patients Considering a Longevity Protocol

A patient interested in longevity interventions should start with what the evidence consistently supports across all five figures discussed here: regular aerobic and resistance exercise, sufficient sleep (7 to 9 hours per night per CDC recommendations [12]), a whole-food dietary pattern, and adequate vitamin D3 status confirmed by serum 25-OH-D measurement.

Off-label drug use, including metformin or rapamycin for longevity, requires a clinician conversation that weighs the preliminary evidence against individual risk factors. NMN and resveratrol are available over-the-counter but carry real costs and uncertain long-term safety profiles in humans. Any patient with prediabetes or early metabolic dysfunction has the strongest (though still limited) evidence base for considering metformin, separate from longevity goals.